Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS Blood and Transplant

UK flag

NHS staff blame cost-cutting for poor diabetes outcomes

Lack of local and national leadership also cited in new ABPI report

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

- PMLiVE

Greater Manchester to control its share of the NHS budget

The north-west English region accounts for 5% of the country's health spending

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

UK doctors call on NHS to use Avastin for wet AMD

Controversial practice of using the drug off-label could save the health service £102m

- PMLiVE

England’s medicine prices ‘too high’

New analysis finds NICE is too lenient on pharma’s price tags

- PMLiVE

England’s Cancer Drugs Fund: Fixing a broken system

Following the culling of 16 medicines from the Fund PME looks at how to improve market access for new oncology products

- PMLiVE

Inventor turns bomb detector into cancer breathalyser

Clinical trials of Billy Boyle's device will be held in two NHS hospitals

- PMLiVE

UK must embrace genomics or face medicines “dark age”

Life sciences minister George Freeman calls for NHS to embrace new data and technology

UK flag

No further price cut for non-PPRS drugs in UK

But industry concerned over long-term plan for statutory medicines on the NHS

- PMLiVE

NICE consults on reducing melanoma cases

New guidance set to focus on diagnosing and managing the skin cancer  

- PMLiVE

Novartis launches another localised NHS eye service in UK

Will provide specialised care to people of Coventry

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links